991 results on '"Hassel, Jessica C"'
Search Results
52. The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin?
53. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
54. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature
55. Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial
56. Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study
57. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases
58. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma
59. Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
60. Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
61. MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection
62. Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets.
63. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
64. C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls
65. Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS
66. Neues vom ASCO 2024 zum Melanom.
67. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
68. Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
69. Therapie des Uveamelanoms*
70. Neues vom AACR und ASCO 2023 für die Dermato‐Onkologie
71. Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events
72. Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
73. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
74. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
75. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
76. “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
77. Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
78. Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT
79. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
80. Rituximab as a therapeutic option for patients with advanced melanoma
81. Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
82. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
83. Fertility preservation in patients with melanoma—a huge relief for those affected
84. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
85. Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach
86. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
87. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
88. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
89. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma:A phase 1 study
90. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab
91. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
92. Macroangiopathy is a positive predictive factor for response to immunotherapy
93. Tebentafusp in Combination With Durvalumab And/or Tremelimumab in Patients With Metastatic Cutaneous Melanoma: A Phase 1 Study
94. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
95. Cancer school—free online seminars for cancer patients, relatives, and other interested persons
96. Divergent response to PD‐L1 inhibition in advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma
97. Abstract LB118: Evidence of tumor response in orbital lesions treated with tebentafusp in metastatic uveal melanoma patients
98. Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM)
99. Data from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
100. Supplementary Table S2 from The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.